EZH2 and myelodysplastic syndrome: MDS with mutations in genes such as TP53, CBL, EZH2, RUNX1, U2AF1, and ASXL1 are more likely to progress to sAML than expected based on traditional scoring systems alone, whereas SF3B1 is associated with a lower risk of progression (72–77).